Examkin

Question

Difficulty: MediumNeoplastic Processes

A 44-year-old man presents to the oncology clinic for treatment planning of newly diagnosed metastatic colorectal cancer. He initially presented to his primary care physician with fatigue and was found to have iron deficiency anemia. A subsequent colonoscopy revealed a 3.5-cm ulcerated mass in the ascending colon, and a computed tomography scan of the abdomen and pelvis showed multiple hepatic metastases. His family history is notable for his father dying of colon cancer at age 48 and a paternal aunt who was treated for endometrial cancer at age 46.

Physical examination reveals pale conjunctivae and a palpable liver edge 3 cm below the right costal margin. Laboratory studies show a hemoglobin of 9.2 g/dL.

Biopsy of the hepatic lesion confirms metastatic adenocarcinoma. Immunohistochemical staining of the biopsy specimen demonstrates intact expression of MLH1 and PMS2 proteins, but absent expression of MSH2 and MSH6 proteins. The oncologist recommends initiating therapy with a programmed cell death protein 1 (PD-1) inhibitor.

Which of the following molecular characteristics best explains why this patient's neoplasm is highly susceptible to this specific pharmacologic therapy?

  1. Accumulation of frameshift mutations resulting in the robust generation of immunogenic neoantigensAnswer
  2. B
    A gain-of-function mutation in the KRAS proto-oncogene that renders the tumor dependent on alternative growth pathways
  3. C
    Epigenetic hypermethylation of the MLH1 promoter region, leading to a tumor microenvironment enriched with cytotoxic T-cells
  4. D
    Inhibition of cytochrome P450 enzymes by tumor-derived cytokines, preventing systemic clearance of the infused antibody
  5. E
    Inherited mutations in the APC gene leading to chromosomal instability and a profusion of colonic adenomas

Answer

Accumulation of frameshift mutations resulting in the robust generation of immunogenic neoantigens
The correct answer correctly identifies the molecular downstream effect of defective DNA mismatch repair (dMMR). In this patient with Lynch syndrome, the loss of MSH2 and MSH6 leads to a failure to correct DNA replication errors. This causes microsatellite instability (MSI), where repetitive DNA sequences accumulate frameshift mutations. These mutations translate into novel, abnormal peptide sequences known as neoantigens. The presence of numerous neoantigens makes the tumor highly visible (immunogenic) to the patient's cytotoxic T-cells. To survive, these tumors typically upregulate immune checkpoint proteins like PD-L1 to suppress the T-cell response. Administering a PD-1 inhibitor blocks this interaction, unleashing a potent, pre-existing immune response against the neoantigen-rich tumor.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and family history.
Early-onset right-sided colon cancer with a family history of colon and endometrial cancers strongly suggests Lynch syndrome.
Identifying the clinical syndrome provides the context for interpreting the molecular testing.
2
Interpret the tumor immunohistochemistry (IHC) results.
The absence of MSH2 and MSH6 proteins indicates defective DNA mismatch repair (dMMR).
IHC is the standard test to determine the functional status of mismatch repair proteins in colorectal cancer.
3
Correlate dMMR with its downstream molecular consequences.
Defective mismatch repair leads to microsatellite instability (MSI), causing numerous frameshift mutations and the production of novel, altered proteins (neoantigens).
Understanding the pathogenesis explains why these specific tumors interact differently with the immune system.
4
Determine the therapeutic rationale for using a PD-1 inhibitor.
The high burden of neoantigens makes the tumor highly immunogenic. The tumor survives by upregulating PD-L1 to exhaust T-cells; a PD-1 inhibitor blocks this evasion, allowing T-cells to attack the tumor.
Connects the underlying cellular pathology directly to the clinical management choice.

Key Concept

Tumors with mismatch repair deficiency (dMMR), such as those seen in Lynch syndrome, develop high microsatellite instability and a massive burden of frameshift-derived neoantigens. This high immunogenicity makes them exceptionally responsive to immune checkpoint inhibitors like PD-1 antibodies.
Estimated Time:1m 30s
Rate this question

Topics

Neoplastic Processes

More questions from this topic